Testing Antiviral Capabilities of Captopril in Mus musculus

Student Author(s)

Kristina Skinner
Nicholas Rozema

Faculty Mentor(s)

Dr. Gerald Griffin

Document Type


Event Date



Existing treatments for Herpes Simplex Virus Type I (HSV-1) have negative effects including nephrotoxicity and increasing rates of drug resistance. The use of Captopril against the Herpes Simplex Virus-1 (HSV-1) provides a possible alternative to other drugs, such as losartan, that produce these negative effects. Captopril is an ACE inhibitor used to treat hypertension or high blood pressure. This project tests the hypothesis that captopril will decrease HSV-1 replication and virulence in vivo. Four groups of C57/BL6 female mice were used in this study. Group 1 received a vehicle control with a mock virus. Group 2 received captopril with a mock virus. Group 3 received vehicle control with 10^6 plaque-forming units of the F strain of HSV-1. Group 4 received captopril with the HSV-1 virus (same titer and strain as Group 3). Mice were infected with the HSV-1 virus via corneal scarification 24 hours after captopril or vehicle treatment began. Treatment with captopril was administered via drinking water at 1.25mg/mL for a total of six days. Pathological analysis and viral gene expression level analysis is ongoing. This work builds upon preliminary in vitro data demonstrating that captopril protects cells from HSV-1 cytopathic effects. Thus, the goal of this work is promising to validate these in vitro results and highlight a novel use for captopril in animals.

This document is currently not available here.